Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORALI Study
2023-504952-87-00Phase 4Authorised
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), steatosis and hepatic fibrosis, sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Liver steatosis and fibrosis by FibroScan. Planned start Mar 2024; status: authorised.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)steatosishepatic fibrosis
Beyond the preview
Go deeper on 2023-504952-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504952-87-00.